NAGE Q4 2025 Earnings — Niagen Bioscience Inc Revenue & Financial Results | Market Cap Arena

NAGENiagen Bioscience Inc

$423M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$34M+16.2% YoY

Gross Profit

$22M64.1% margin

Operating Income

$2M6.2% margin

Net Income

$4M12.2% margin

EPS (Diluted)

$0.05

QoQ Revenue Growth

-0.4%

Cash Flow

Operating Cash Flow

$624,000

Free Cash Flow

$523,000

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$106M

Total Liabilities

$30M

Stockholders' Equity

$77M

Cash & Equivalents

$65M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$34M	$29M	+16.2%
Gross Profit	$22M	$18M	+19.3%
Operating Income	$2M	$7M	-70.4%
Net Income	$4M	$7M	-42.4%